Pneumococcal sepsis in aged patients - implications for the vaccination of seniors against pneumococci
Abstract
In the years 2005-2010 pneumococci were isolated in the Limbach laboratory/Heidelberg from blood cultures of 1,085 patients. Obviously, older patients are more prone to these bacteria, since 66 % of the patients were older than 60 years. All isolates were susceptible to cefotaxime; 3 % of isolates were resistant to penicillin, 2 % were resistant to levofloxacin and 15 % were resistant to erythromycin. From 457 out of the isolates serotyping was achieved: more than 80 % of the isolates were covered by the 23-valent vaccine. This means that particularly old people should be vaccinated against pneumococci, because they will profit probably most from such preventive measurements.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 1,085 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.